D. 
To evaluate markers of HIV disease activity in allogeneic BMT patients receiving adoptive 
immunotherapy with CD8 + T„ clones. 
5. Patient Selection 
This study will enroll a subset of patients eligible for Protocol #526. All patients entered onto #696 
will receive antiretroviral therapy as outlined in protocol 526 and will not be on other experimental protocols. 
A minimum of five and a maximum of fifteen HIV-seropositive patients undergoing allogeneic BMT from 
HLA-identical related donors for non-Hodgkin’s lymphoma in first remission or first relapse with limited 
disease will be enrolled. 
A. Eligibility criteria for study entry: Patients must meet all of the following criteria: 
1. The patients entering into the adoptive immunotherapy study must have a scheduled 
transplant date that is at least three months following the initial visit to permit 
adequate time to generate and genetically modify T cells for therapy. Thus, the 
clinical coordinator will contact the investigator to arrange for consultation with the 
patient and the prospective marrow donor. If T cells are not generated for therapy, 
the patients will be treated on protocol #526. 
2. The bone marrow donor must be >_ 16 years of age. 
3. Patients must be >_ 18 years, <_ 45 years of age. 
4. The patient must be HIV-seropositive as determined by Western blot and either HIV-1 
culture positive, p24 antigenemic or positive by PCR for HIV-1 DNA or RNA. 
5. The patient is a candidate for allogeneic BMT for the treatment of non-Hodgkin’s 
lymphoma and has an HLA-identical related donor who is HIV-1 seronegative and 
PCR negative for HIV-1 DNA. 
6. All patients will receive azidothymidine beginning at least 2 weeks pretransplant and 
continuing for a minimum of 12 months post-transplant unless adverse effects occur. 
7. Patients entering this study will require insertion of a triple lumen central venous 
catheter. 
8. Signed informed consent that fulfills Institutional Review Board guidelines must be 
obtained. 
B. Exclusion criteria 
1. Patients with life-threatening infection which would preclude BMT are not eligible. If 
the infection resolves, they can be re-evaluated as candidates for this protocol. The 
following past or present infections, however, permanently preclude patient eligibility: 
Mycobacterium avium intracellular , toxoplasmosis, cryptococcoses, cytomegalovirus 
retinitis or pneumonitis and acyclovir-resistant herpes simplex infection. 
2. Patients with visceral involvement of Kaposi’s Sarcoma (e.g. lung, liver etc.). 
3. Prior zidovudine therapy of greater than 90 days duration. If a patient has received 
zidovudine for more than 90 days, the patient will be eligible for the protocol if ID 50 
in vitro sensitivity testing of HIV isolates is less than 1/x molar. 
4. Pregnant women, nursing mothers or women of childbearing potential not employing 
appropriate contraception or abstinence. 
5. Patients with abnormal neurocognitive neurologic examination as evaluated by 
consulting neurologist. 
6. Absolute CD4 cell count <200//zl at the time of referral. 
7. Patients with prior radiation therapy precluding the use of TBI in the preparative 
regimen. This includes: 
Recombinant DNA Research, Volume 15 
[617] 
